Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$14.12
-0.20-1.40%
At close: -
$14.12
0.000.00%
After Hours: 4:01 PM EDT
Comments
Loading...
Inhibrx Biosciences Analyst Ratings and Price Targets | NASDAQ:INBX | Benzinga
Inhibrx Biosciences Inc has a consensus price target of $47 based on the ratings of 5 analysts. The high is $60 issued by Evercore ISI Group on October 5, 2022. The low is $35 issued by JMP Securities on May 10, 2023. The 3 most-recent analyst ratings were released by JMP Securities on November 20, 2023, August 23, 2023, and May 10, 2023, respectively. With an average price target of $29.67 between JMP Securities, there's an implied 110.10% upside for Inhibrx Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
Credit Suisse
Evercore ISI Group
1calculated from analyst ratings
Analyst Ratings for Inhibrx Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/18/2025 | Buy Now | — | Citizens Capital Markets | Reni Benjamin45% | — | Reiterates | Market Perform → Market Perform | Get Alert |
| 01/22/2025 | Buy Now | — | JMP Securities | Reni Benjamin45% | — | Reiterates | Market Perform → Market Perform | Get Alert |
| 07/23/2024 | Buy Now | — | JMP Securities | Reni Benjamin45% | — | Initiates | → Market Perform | Get Alert |
| 01/23/2024 | Buy Now | — | JMP Securities | Reni Benjamin45% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 11/20/2023 | Buy Now | 91.22% | JMP Securities | Reni Benjamin45% | → $27 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/23/2023 | Buy Now | 91.22% | JMP Securities | Reni Benjamin45% | $35 → $27 | Maintains | Outperform | Get Alert |
| 05/10/2023 | Buy Now | 147.88% | JMP Securities | Benjamin Chaiken63% | → $35 | Reiterates | → Market Outperform | Get Alert |
| 03/08/2023 | Buy Now | 147.88% | JMP Securities | Benjamin Chaiken63% | $40 → $35 | Maintains | Market Outperform | Get Alert |
| 03/07/2023 | Buy Now | 225.78% | Credit Suisse | Judah Frommer65% | → $46 | Reiterates | → Outperform | Get Alert |
| 11/08/2022 | Buy Now | 225.78% | Credit Suisse | Judah Frommer65% | $48 → $46 | Maintains | Outperform | Get Alert |
| 10/05/2022 | Buy Now | 324.93% | Evercore ISI Group | Gavin Clark-Gartner39% | $54 → $60 | Maintains | Outperform | Get Alert |
| 08/09/2022 | Buy Now | 239.94% | Credit Suisse | Judah Frommer65% | $53 → $48 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Inhibrx Biosciences (INBX) stock?
The latest price target for Inhibrx Biosciences (NASDAQ:INBX) was reported by Citizens Capital Markets on March 18, 2025. The analyst firm set a price target for $0.00 expecting INBX to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Inhibrx Biosciences (INBX)?
The latest analyst rating for Inhibrx Biosciences (NASDAQ:INBX) was provided by Citizens Capital Markets, and Inhibrx Biosciences reiterated their market perform rating.
When was the last upgrade for Inhibrx Biosciences (INBX)?
There is no last upgrade for Inhibrx Biosciences
When was the last downgrade for Inhibrx Biosciences (INBX)?
The last downgrade for Inhibrx Biosciences Inc happened on January 23, 2024 when JMP Securities changed their price target from N/A to N/A for Inhibrx Biosciences Inc.
When is the next analyst rating going to be posted or updated for Inhibrx Biosciences (INBX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inhibrx Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inhibrx Biosciences was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.
Is the Analyst Rating Inhibrx Biosciences (INBX) correct?
While ratings are subjective and will change, the latest Inhibrx Biosciences (INBX) rating was a reiterated with a price target of $0.00 to $0.00. The current price Inhibrx Biosciences (INBX) is trading at is $14.12, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.